Ivo Abraham

Ivo Abraham

Professor of Practice

Ivo Abraham is a professor in the Department of Pharmacy Practice, with joint appointments in the Department of Family and Community Medicine (College of Medicine – Tucson) and the Department of Clinical Translational Sciences (College of Health Sciences). He has also served on the faculty of Case Western Reserve University (Cleveland, OH), University of Virginia (Charlottesville, VA), and (part-time) KU Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, FL), Rijksuniversiteit Groningen (Groningen, The Netherlands), New York University (New York, NY), University of Pennsylvania (Philadelphia, PA) Chang Gung University (Kwei-Shan Tao-Yuan, Taiwan), and Hyogo University (Akashi, Japan). He has lectured, consulted, and conducted research throughout the Americas, Europe, Asia, Australasia, and Africa.

A nurse by profession and a health outcomes, effectiveness, and economics scientist by trade, his research has been funded since 1984 by public funding agencies, foundations, and corporations. He coordinates the Senza Nome (Italian, “without a name”) research group, which, on the outcomes and effectiveness side, studies how variability in (drug-centric) treatment regimens is associated with variability in patient outcomes; and how practicing in accordance with evidence-based guidelines is associated with patient outcomes. On the economics side, and focusing mainly on pharmacotherapeutics but also models of care, his group tries to reconcile four questions: what is the clinical effect? how much does it cost? is it worth it? and, can we afford it?

He has (co-)authored 520+ articles and 80+ chapters, and has (co-)edited 50+ books, monographs, and journal issues. Having been a member of several editorial boards, he currently serves as the Quantitative Methods Editor of JAMA Dermatology and as Editor-in-Chief of the Journal of Medical Economics.

In the US, he has served as chartered or ad hoc study section member for the NIH, NIMH, AHRQ, VA, and NSF since 1985. He has served as an expert adviser to the Innovative Medicines and Innovative Health Initiatives, a joint 7.4 billion euro undertaking of the European Union and the industry to stimulate research and innovation in human therapeutics, vaccines, as well as diagnostics and other technologies, from their inception in 2008. He has also served as expert to various public and private funding agencies in European, Asian, and North American countries.

His educational and scientific honors and awards include several named lectureships in the US and abroad; and an invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008), which he conducted at Hyogo University and Aomori University. He is most proud of honors awarded by the R. Ken Coit College of Pharmacy, including Graduate Mentor of the Year (2017), the Theodore G. Tong Distinguished Leadership and Service Award (2018), the Findlay E. Russell, MD, PhD, Distinguished Citizen Award (2019), and the Dean’s Outstanding Service Award (2022).

Representative Publications (past 5 years)

Abraham I, Calamia M, MacDonald KM. Should a systematic review be required in a clinical trial report? Perhaps, but not yet. JAMA Network Open 2023;6:e234226. PMID: 36951867 DOI: 10.1001/jamanetworkopen.2023.4226

Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I. Economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Review of Pharmacoeconomics and Outcomes Research 2023;23:309-316. PMID: 36637419  DOI: 10.1080/14737167.2023.2169135

Abraham I. Trends, changes, and disruptions: the fragile economics of cancer treatments. The Oncologist 2023;28:193-195. PMID: 36640143  DOI: 10.1093/oncolo/oyac258

Alrawashdh N, McBride A, Erstad B, Sweasy J, Persky DO, Abraham I. Cost-effectiveness and economic burden analyses of all first-line treatments of chronic lymphocytic leukemia. Value in Health 2022;25:1685-1695. PMID: 35537984  DOI: 10.1016/j.jval.2022.04.001

Obeng-Kusi M, Habila M, Roe D, Erstad B, Abraham I. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries. Journal of Medical Economics 2021;24(Suppl 1):1-13. PMID: 34866541  DOI: 10.1080/13696998.2021.2002092

Choi BM, Abraham RB, Halawah H, Calamia M, Obeng-Kusi M, Alrawashdh N, Arku D, Abraham I. Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. Journal of Medical Economics 2021;24(Suppl 1):34-41. PMID: 34866529  DOI: 10.1080/13696998.2021.2007705

Alkhatib NS, Abraham I. The Six Delta platform for outcome-based pricing of pharmaceuticals. Journal of Medical Economics 2020;23:1209-1214. PMID: 32930629  DOI: 10.1080/13696998.2020.1824161

Almutairi AR, Alkhatib N, Oh M, Curiel-Lewandrowski C, Babiker HM, Cranmer L, McBride A, Abraham I. Economic evaluation of talimogene laherparepvec plus ipilimumab combination therapy versus ipilimumab in patients with advanced unresectable melanoma. JAMA Dermatology 2019;155:22-28. PMID: 30477000  DOI: 10.1001/jamadermatol.2018.3958

Gharaibeh M, McBride A, Alberts DS, Slack M, Erstad B, Alsaid N, Bootman JL, Abraham I. Economic evaluation for USA of systemic chemotherapies as first-line treatment of metastatic pancreatic cancer. Pharmacoeconomics 2018;36:1273-1284. PMID: 29948964  DOI: 10.1007/s40273-018-0678-6.

Oh YM, McBride A, Yun S, Bhattacharjee S, Slack M, Martin J, Jeter J, Abraham I. BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis. Journal of the National Cancer Institute 2018;110:1178-1189. PMID: 30380096  DOI: 10.1093/jnci/djy148


  • BS, Psychiatric Nursing, University College Leuven (Leuven, Belgium), 1979
  • MS, Psychiatric-Mental Health Nursing, University of Michigan, 1982
  • PhD, Clinical Research, University of Michigan, 1984